Targos and AKESOgen have formed a strategic partnership to enable a comprehensive biomarker service for clinical trials and molecular pathology. AKESOgen is a CLIA compliant integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. The company supports a number of world class organizations including the CDC, the US Department of Veteran’s Affairs, the American Cancer Society and Kaiser Permanente. AKESOgen’s flagship clinical test is a clinical cytogenomics array for a wide-ranging spectrum of cancers. AKESOgen also provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit

WuXi PharmaTech, China

Targos and WuXi PharmaTech are collaborating in Clinical Biomarker Services and Pathology Training in China. WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.For more information, visit

Pathologie Nordhessen, Germany

Pathologie Nordhessen is a national community pathology practice specializing in anatomic pathology and gynecological cytology with established networks in diagnostic pathology, teaching and research. Collaborations exist with the Universities of Göttingen and Marburg as well as numerous national and international partners. A molecular pathology network has been established with the University Medical Center Göttingen.

Its 11 board certified pathologists work with local community hospitals and oncologists to bring the standard of care treatment into their community.  The board certified pathologists are specialized in a variety of fields such as breast, gastric, prostate, colorectal cancer and haematopathology.  

The Pathologie Nordhessen has a very close relationship with Targos molecular pathology GmbH, which is a center for predictive cancer research and reference testing for predictive biomarkers performed as a world-wide service.

Institute of Pathology, University Hospital Cologne, Germany

The Institute of Pathology belonging to the University Hospital Cologne is a central diagnostic facility in which samples from more than 50.000 patients are analyzed per year. The institute employs 126 employees including 15 board-certified and 9 resident pathologists. Molecular diagnostics include mutational analysis and fluorescence in situ hybridization (FISH) of a wide range of biomarkers to obtain a detailed diagnosis or optimal treatment option. Next-Generation Sequencing techniques and cancer genome profiling is also implemented into routine diagnostics.

The institute is accredited according to DIN EN ISO/IEC 17020 "Conformity assessment - General criteria for the operation of various types of bodies performing inspection”. Continued professional development training courses are offered in collaboration with the International Academy for Pathology (IAP). Furthermore, the Institute of Pathology is a reference institute for QUIP inter-laboratory proficiency testing.

As part of the center for excellence for integrated oncology, one of the institute’s major objectives is to adapt innovations from research into clinical practice.  Other initiatives include the development of novel approaches in the diagnosis and treatment of cancer and rapid integration of molecular diagnostic tests into routine testing thereby enabling patient screening for early proof-of-principle clinical trials.

The collaboration with Targos is another step towards this goal. Targos has 15 years of experience with highly standardized biomarker services in clinical trials. As mutational analysis and in particular genomic sequencing is becoming increasingly important for patient recruitment in clinical trials, the experience of Targos with clinical trials is combined with the technical expertise of the institute’s sequencing units with special emphasis on Next-Generation Sequencing.

Department of Pathology, University Medical Center Göttingen (UMG), Germany

The Department of Pathology is involved in patient care of complex diseases in one of the major tertiary medical center in Lower Saxony. The scientific focus is the study of mediastinal tumors, especially thymoma and thymic carcinoma, as well as soft- tissue tumors. Other major interests are insulin signaling in various tumors (including colorectal, breast and prostate cancer) and imaging techniques. Furthermore, the department is committed to studies pertaining to the central research focus in oncology at the UMG, therapy resistance, toxicity and tumor progression using a model system for colorectal cancer.

The department is also involved in various clinical trials and experimental research with other university departments and German Cancer Networks.

Since 2012, the department has forged a strong collaboration with Targos GmbH in IHC and FISH studies pertaining to breast, gastric, prostate, colorectal cancer and hematopathology.